{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:45:07Z","timestamp":1790210707532,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017607","name":"Shenzhen Municipal Fundamental Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025A1515011286"],"award-info":[{"award-number":["2025A1515011286"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024A1515011286"],"award-info":[{"award-number":["2024A1515011286"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403200"],"award-info":[{"award-number":["2023YFC3403200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20220818100402004"],"award-info":[{"award-number":["JCYJ20220818100402004"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ymthe.2025.09.025","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:22:44Z","timestamp":1757773364000},"page":"6265-6281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Harnessing mRNA-encoded PcrV-targeting monoclonal antibodies for combating antibiotic-resistant P. aeruginosa infections"],"prefix":"10.1016","volume":"33","author":[{"given":"Xingyun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Rcheulishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiubiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng George","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.09.025_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41392-022-01056-1","article-title":"Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.09.025_bib2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.copbio.2008.10.002","article-title":"Antibodies for the treatment of bacterial infections: current experience and future prospects","volume":"19","author":"Bebbington","year":"2008","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ymthe.2025.09.025_bib4","article-title":"Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace","volume":"36","author":"Nwobodo","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ymthe.2025.09.025_bib5","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2025.09.025_bib6","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1038\/s41467-019-13108-2","article-title":"An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.025_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40204-1","article-title":"Monoclonal antibody levels and protection from COVID-19","volume":"14","author":"Stadler","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.025_bib8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrmicro2199","article-title":"The type III secretion system of Pseudomonas aeruginosa: infection by injection","volume":"7","author":"Hauser","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib9","first-page":"1983","article-title":"PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates","volume":"218","author":"Tabor","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymthe.2025.09.025_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-023-00672-4","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","volume":"8","author":"Wang","year":"2023","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2025.09.025_bib11","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","article-title":"Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial","volume":"40","author":"Francois","year":"2012","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ymthe.2025.09.025_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02565-17","article-title":"MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model","volume":"62","author":"Le","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2025.09.025_bib13","doi-asserted-by":"crossref","first-page":"629.e1","DOI":"10.1016\/j.cmi.2018.08.004","article-title":"Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults","volume":"25","author":"Ali","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ymthe.2025.09.025_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13054-022-04204-9","article-title":"Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial","volume":"26","author":"Chastre","year":"2022","journal-title":"Crit. Care"},{"key":"10.1016\/j.ymthe.2025.09.025_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jcf.2017.12.006","article-title":"KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa","volume":"17","author":"Jain","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ymthe.2025.09.025_bib16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.09.025_bib17","article-title":"Strategies and Considerations for Improving Recombinant Antibody Production and Quality in Chinese Hamster Ovary Cells","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40259-020-00412-3","article-title":"In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies","volume":"34","author":"Patel","year":"2020","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2025.09.025_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.09.025_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41422-022-00630-0","article-title":"Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters","volume":"32","author":"Deng","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2025.09.025_bib21","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.09.025_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41467-017-00576-7","article-title":"An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model","volume":"8","author":"Patel","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.025_bib23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.it.2021.10.008","article-title":"Single B cell technologies for monoclonal antibody discovery","volume":"42","author":"Pedrioli","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib24","doi-asserted-by":"crossref","first-page":"L591","DOI":"10.1152\/ajplung.00335.2013","article-title":"Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa","volume":"306","author":"Lovewell","year":"2014","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.crimmu.2023.100057","article-title":"Battle royale: Immune response on biofilms - host-pathogen interactions","volume":"4","author":"Cangui-Panchi","year":"2023","journal-title":"Curr. Res. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41522-025-00738-2","article-title":"Immune system dynamics in response to Pseudomonas aeruginosa biofilms","volume":"11","author":"Sahu","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.ymthe.2025.09.025_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.tim.2025.05.004","article-title":"Pseudomonas aeruginosa: persistence beyond antibiotic resistance","author":"La Rosa","year":"2025","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib28","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212032","article-title":"Functional vulnerability of liver macrophages to capsules defines virulence of blood-borne bacteria","volume":"219","author":"An","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.09.025_bib29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1189\/jlb.3VMR0315-080R","article-title":"Emerging functions of serum amyloid A in inflammation","volume":"98","author":"Ye","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.803244","article-title":"Alpha-2-Macroglobulin in Inflammation, Immunity and Infections","volume":"12","author":"Vandooren","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00089","article-title":"The Role of Cytochromes P450 in Infection","volume":"9","author":"Stavropoulou","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib32","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.02643-14","article-title":"A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models","volume":"58","author":"Warrener","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2025.09.025_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02381-22","article-title":"PopB-PcrV Interactions Are Essential for Pore Formation in the Pseudomonas aeruginosa Type III Secretion System Translocon","volume":"13","author":"Kundracik","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.ymthe.2025.09.025_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13110776","article-title":"The Role of Pseudomonas aeruginosa Virulence Factors in Cytoskeletal Dysregulation and Lung Barrier Dysfunction","volume":"13","author":"Wagener","year":"2021","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ymthe.2025.09.025_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/1040841X.2018.1538934","article-title":"Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs","volume":"45","author":"Sanchez","year":"2019","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1541704","article-title":"Characterization of carbapenem-resistant Klebsiella pneumoniae in bloodstream infections: antibiotic resistance, virulence, and treatment strategies","volume":"15","author":"Zhong","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ymthe.2025.09.025_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and Challenges in the Delivery of mRNA-based Vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.09.025_bib38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.09.025_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13010097","article-title":"Affordable mRNA Novel Proteins, Recombinant Protein Conversions, and Biosimilars-Advice to Developers and Regulatory Agencies","volume":"13","author":"Niazi","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2025.09.025_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/antib10040037","article-title":"Engineered mRNA and the Rise of Next-Generation Antibodies","volume":"10","author":"Sanz","year":"2021","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.ymthe.2025.09.025_bib41","first-page":"143","article-title":"Types of acute phase reactants and their importance in vaccination","volume":"12","author":"Khalil","year":"2020","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.ymthe.2025.09.025_bib42","article-title":"Acute phase reactants as novel predictors of cardiovascular disease","volume":"2012","author":"Ahmed","year":"2012","journal-title":"ISRN Inflamm."},{"key":"10.1016\/j.ymthe.2025.09.025_bib43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.025_bib44","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1016\/j.cell.2023.10.002","article-title":"Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa","volume":"186","author":"Simonis","year":"2023","journal-title":"Cell"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:56:39Z","timestamp":1766152599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625007531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1525001625007531"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.025","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing mRNA-encoded PcrV-targeting monoclonal antibodies for combating antibiotic-resistant P. aeruginosa infections","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}